Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Celgene Corporation.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00046735
First received: October 2, 2002
Last updated: September 30, 2009
Last verified: September 2009

October 2, 2002
September 30, 2009
June 2002
August 2006   (final data collection date for primary outcome measure)
To identify the MTD and safety of CDC-501 when given in a 6-wk cycle of daily administration of CDC-501 for 4 wks followed by a 2-wk rest in doses of 5 mg/day up to 25 mg/day in pts with solid tumors that are refractory after standard treatment. [ Time Frame: 6-week cycle comprising daily administration of CDC-501 for 4 weeks followed by a 2-week rest ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00046735 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors

To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.

Identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Neoplasms
Drug: Lenalidomide
The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
Experimental: 1
Intervention: Drug: Lenalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
24
December 2009
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient must understand and voluntarily sign an informed consent document.
  2. Age 18 years at the time of signing Informed Consent
  3. Histologically or cytologically documented solid tumors that are refractory to standard/conventional therapy or for which no standard/conventional therapy exists.
  4. Patients must have at least one measurable or non-measurable lesion according to the RECIST Criteria (Appendix I).
  5. Patient has an ECOG (Zubrod) performance status of ≤ 2.
  6. Approximate life expectancy greater than 3 months.
  7. Laboratory tests within these ranges:

    • Absolute neutrophil count ≥ 1,500/μlL
    • Platelet count ≥100,000/μL
    • Serum creatinine ≤1.5 mg/dL
    • Total bilirubin ≤1.5 mg/dL
    • AST (SGOT)/ALT(SGPT) ≤ 2 x upper limit of normal (ULN) or ≤ 5 x ULN if hepatic metastases present
  8. The following prior treatments are allowable under this protocol:
  9. Radiation, if discontinued at least 4 weeks prior to treatment under this protocol Chemotherapy, if discontinued at least 4 weeks prior to treatment under this protocol, and at least 6 weeks prior to treatment under this protocol for prior nitrosurea or mitomycin-C treatment
  10. Hormonal therapy for cancer, if discontinued at least 4 weeks prior to treatment under this protocol
  11. Other investigational drugs, if discontinued at least 4 weeks prior to treatment under this protocol
  12. Surgery, if minor surgery occurred at least 2 weeks prior to treatment under this protocol, or at least 4 weeks since major surgery
  13. Patient must be able to adhere to the study visit schedule and other protocol requirements.
  14. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days prior to baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria

  1. Myocardial infarction within the previous 6 months, unstable angina,symptomatic congestive heart failure, or other significant uncontrolled cardiac arrhythmia.
  2. Cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or other significant thromboembolic event in the previous 6 months.
  3. Active infection, including known human immunodeficiency virus (HIV) positivity or acquired-immunodeficiency-syndrome (AIDS)-related illness.
  4. CNS metastases, unless controlled by previous radiation and the patient is neurologically stable.
  5. Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent or limit survival to less than 3 months.
  6. Pregnant or nursing females.Female patients of childbearing potential who are unwilling to use reliable contraceptive methods.
  7. Any condition, including the presence of laboratory abnormalities, which in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00046735
CC-5013-ST-003
Not Provided
Robert Knight, VP Hematology, Celgene Corporation
Celgene Corporation
Not Provided
Study Director: Robert Knight, MD Celgene Corporation
Celgene Corporation
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP